$ODYY
Odyssey Group of Companies Stock $odyy

$odyy Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000168316823007508 Filed on October 30, 2023

Income Statement

Concept	2023 Q4	2023
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$25.84K	$201.3K
YoY Change	-92.7%	-84.71%
% of Gross Profit
Depreciation & Amortization		$0.00
YoY Change		-100.0%
% of Gross Profit
Operating Expenses	$25.84K	$201.3K
YoY Change	-92.7%	-84.71%
Operating Profit	-$847.2K	-$5.314M
YoY Change	-59.22%	-34.45%
Interest Expense	$190.9K	$614.1K
YoY Change	167.68%	-26.57%
% of Operating Profit
Other Income/Expense, Net	$65.00	$11.14K
YoY Change	-113.71%	-77.27%
Pretax Income
YoY Change
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$538.0K	-$5.919M
YoY Change	-74.97%	-29.9%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01	-$0.07
Diluted Earnings Per Share	-$0.01	-$0.07
COMMON SHARES
Basic Shares Outstanding	81.73M shares	82.68M shares
Diluted Shares Outstanding	81.02M shares	82.68M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$197.9K	$36.87K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables		$276.6K
Total Short-Term Assets	$563.1K	$405.9K
YoY Change	-31.09%	-22.9%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$48.96K	$49.91K
YoY Change	-3.13%	15.36%
TOTAL ASSETS
Total Short-Term Assets	$563.1K	$405.9K
Total Long-Term Assets	$48.96K	$49.91K
Total Assets	$612.0K	$455.8K
YoY Change	-29.47%	-19.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.851M	$1.798M
YoY Change	-22.0%	16.01%
Accrued Expenses		$13.75K
YoY Change		0.0%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.830M	$6.612M
YoY Change	9.26%	26.82%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.830M	$6.612M
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$60.64M	-$60.10M
YoY Change	7.65%	10.93%
Common Stock	$81.73K	$79.07K
YoY Change	13.53%	1.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.218M	-$6.156M
YoY Change
Total Liabilities & Shareholders Equity	$612.0K	$455.8K
YoY Change	-29.47%	-19.99%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$538.0K	-$5.919M
YoY Change	-74.97%	-29.9%
Depreciation, Depletion And Amortization		$0.00
YoY Change		-100.0%
Cash From Operating Activities	-$59.91K	-$1.475M
YoY Change	-78.96%	-53.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$10.06K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$220.9K	$1.449M
YoY Change	-18.39%	-47.05%
NET CHANGE
Cash From Operating Activities	-$59.91K	-$1.475M
Cash From Investing Activities	$0.00	-$10.06K
Cash From Financing Activities	$220.9K	$1.449M
Net Change In Cash	$161.0K	-$35.67K
YoY Change	-830.73%	-91.87%
FREE CASH FLOW
Cash From Operating Activities	-$59.91K	-$1.475M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001626644
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-07-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-56196
CY2023	dei	Entity Registrant Name EntityRegistrantName	ODYSSEY HEALTH, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1022125
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2300 West Sahara Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800 - #4012
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89102
CY2023	dei	City Area Code CityAreaCode	(702)
CY2023	dei	Local Phone Number LocalPhoneNumber	780-6559
CY2023	dei	Security12b Title Security12bTitle	Common Stock ($0.001 par value)
CY2023	dei	Trading Symbol TradingSymbol	ODYY
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	11007885	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	81734061	shares
CY2023	dei	Auditor Firm AuditorFirmId	76
CY2023	dei	Auditor Name AuditorName	Turner, Stone & Company, L.L.P
CY2023	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2023Q3	us-gaap	Cash Cash	36865	usd
CY2022Q3	us-gaap	Cash Cash	72534	usd
CY2023Q3	ODYY	Research And Development Rebate Due From Australian Government ResearchAndDevelopmentRebateDueFromAustralianGovernment	276566	usd
CY2022Q3	ODYY	Research And Development Rebate Due From Australian Government ResearchAndDevelopmentRebateDueFromAustralianGovernment	366475	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	92457	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	87408	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	405888	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	526417	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49905	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	43260	usd
CY2023Q3	us-gaap	Assets Assets	455793	usd
CY2022Q3	us-gaap	Assets Assets	569677	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1797656	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1549568	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1402348	usd
CY2022Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	896700	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	142032	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	110063	usd
CY2023Q3	us-gaap	Assets Sold Under Agreements To Repurchase Repurchase Liability AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability	1125026	usd
CY2022Q3	us-gaap	Assets Sold Under Agreements To Repurchase Repurchase Liability AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability	1125026	usd
CY2023Q3	ODYY	Notes Payable Related Parties Classified Current1 NotesPayableRelatedPartiesClassifiedCurrent1	125000	usd
CY2022Q3	ODYY	Notes Payable Related Parties Classified Current1 NotesPayableRelatedPartiesClassifiedCurrent1	125000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	280340	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	48063	usd
CY2023Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2019660	usd
CY2022Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	1406937	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6611722	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5213294	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79067879	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79067879	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77860563	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77860563	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	79068	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	77861	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53862378	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49456476	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60097375	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54177954	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6155929	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4643617	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	455793	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	569677	usd
CY2023	ODYY	Research And Development In Process1 ResearchAndDevelopmentInProcess1	170000	usd
CY2022	ODYY	Research And Development In Process1 ResearchAndDevelopmentInProcess1	0	usd
CY2023	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	201329	usd
CY2022	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	1317024	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2820311	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3870465	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2122375	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2919091	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5314015	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8106580	usd
CY2023	us-gaap	Interest Expense InterestExpense	614083	usd
CY2022	us-gaap	Interest Expense InterestExpense	836294	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	8677	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	498743	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5919421	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8444131	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82677354	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88995280	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82677354	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	88995280	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-2767354	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1781650	usd
CY2022	ODYY	Common Stock Issued In Connection With Prevacus Milestone CommonStockIssuedInConnectionWithPrevacusMilestone	0	shares
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2088815	usd
CY2022	ODYY	Common Stock Issued In Connection With Debt Financing CommonStockIssuedInConnectionWithDebtFinancing	68718	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2469222	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	159463	usd
CY2022	ODYY	Return Of Shares To Treasury ReturnOfSharesToTreasury	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8444131	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4643617	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2820311	usd
CY2023	ODYY	Common Stock Issued In Debt Financing CommonStockIssuedInDebtFinancing	13443	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	345135	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	580220	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	478000	usd
CY2023	ODYY	Common Stock Issued In Option Purchase Agreement CommonStockIssuedInOptionPurchaseAgreement	170000	usd
CY2023	ODYY	Return Of Shares To Treasury ReturnOfSharesToTreasury	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5919421	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6155929	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-5919421	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-8444131	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3416	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2374	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2820311	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3870465	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	532434	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	687429	usd
CY2022	ODYY	Stock Issued For Inprocess Research And Development StockIssuedForInprocessResearchAndDevelopment	170000	usd
CY2021	ODYY	Stock Issued For Inprocess Research And Development StockIssuedForInprocessResearchAndDevelopment	0	usd
CY2022	us-gaap	Other Noninterest Expense OtherNoninterestExpense	1750	usd
CY2021	us-gaap	Other Noninterest Expense OtherNoninterestExpense	68718	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5049	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	33873	usd
CY2022	ODYY	Decrease Increase Research And Development Rebate Due From Australian Government DecreaseIncreaseResearchAndDevelopmentRebateDueFromAustralianGovernment	-89909	usd
CY2021	ODYY	Decrease Increase Research And Development Rebate Due From Australian Government DecreaseIncreaseResearchAndDevelopmentRebateDueFromAustralianGovernment	366475	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	248088	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	324785	usd
CY2022	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	505648	usd
CY2021	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	637213	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	78219	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	77712	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1474696	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3175783	usd
CY2022	ODYY	Intellectual Property IntellectualProperty	10061	usd
CY2021	ODYY	Intellectual Property IntellectualProperty	45220	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	903868	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	375000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	35000	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	107269	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	580220	usd
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2469222	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1449088	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2736953	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-35669	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-484050	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72534	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	556584	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36865	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72534	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	954	usd
CY2022	ODYY	Common Stock Issued For Conversion Of Notes Payable And Related Accrued Interest CommonStockIssuedForConversionOfNotesPayableAndRelatedAccruedInterest	478000	usd
CY2021	ODYY	Common Stock Issued For Conversion Of Notes Payable And Related Accrued Interest CommonStockIssuedForConversionOfNotesPayableAndRelatedAccruedInterest	0	usd
CY2022	ODYY	Common Stock Issued For Debt Financing Commitment Shares CommonStockIssuedForDebtFinancingCommitmentShares	0	usd
CY2021	ODYY	Common Stock Issued For Debt Financing Commitment Shares CommonStockIssuedForDebtFinancingCommitmentShares	68718	usd
CY2022	ODYY	Common Stock Issued In Exchange For Closing Costs CommonStockIssuedInExchangeForClosingCosts	13443	usd
CY2021	ODYY	Common Stock Issued In Exchange For Closing Costs CommonStockIssuedInExchangeForClosingCosts	0	usd
CY2022	ODYY	Warrants Issued In Connection With Financings WarrantsIssuedInConnectionWithFinancings	345135	usd
CY2021	ODYY	Warrants Issued In Connection With Financings WarrantsIssuedInConnectionWithFinancings	0	usd
CY2022	ODYY	Original Issue Discount On Debt OriginalIssueDiscountOnDebt	98048	usd
CY2021	ODYY	Original Issue Discount On Debt OriginalIssueDiscountOnDebt	0	usd
CY2022	ODYY	Beneficial Conversion Feature Recognized BeneficialConversionFeatureRecognized	0	usd
CY2021	ODYY	Beneficial Conversion Feature Recognized BeneficialConversionFeatureRecognized	200100	usd
CY2022	ODYY	Accounts Payable Converted Into Common Stock AccountsPayableConvertedIntoCommonStock	0	usd
CY2021	ODYY	Accounts Payable Converted Into Common Stock AccountsPayableConvertedIntoCommonStock	20000	usd
CY2022	ODYY	Increase In Principal Of Notes Payable IncreaseInPrincipalOfNotesPayable	406132	usd
CY2021	ODYY	Increase In Principal Of Notes Payable IncreaseInPrincipalOfNotesPayable	225000	usd
CY2022	ODYY	Common Stock Issued For Prevacus Milestone CommonStockIssuedForPrevacusMilestone	0	usd
CY2021	ODYY	Common Stock Issued For Prevacus Milestone CommonStockIssuedForPrevacusMilestone	1000	usd
CY2022	ODYY	Shares Returned To Treasury SharesReturnedToTreasury	8800	usd
CY2021	ODYY	Shares Returned To Treasury SharesReturnedToTreasury	23530	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_807_eus-gaap--NatureOfOperations_z0inT3KjZ7Pk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1. <span id="xdx_826_zAZ2NJdJwLLk">Nature of Operations and Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have clinical utility and will generate positive cash flow. Our business model is to develop or acquire medical related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties. We have three different life saving technologies; the CardioMap® heart monitoring and screening device, the Save a Life choking rescue device and a unique neurosteroid drug compound intended to treat concussions and rare brain disorders. We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products and we will apply for trademarks and patents once we have developed proprietary products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration ("FDA") clearance or approval to market our products will be required to sell in the United States. In addition, it would require additional European union or country specific clearance or approvals to sell internationally.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not recognize any revenues for the years ended July 31, 2023 (“fiscal 2023”) or 2022 (“fiscal 2022”) and we had an accumulated deficit of $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230731_zgpKhsbfHkNd" title="Accumulated deficit">60,097,375</span> as of July 31, 2023. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations. Cash available at July 31, 2023 of $<span id="xdx_90A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230731_z6OhVF655986" title="Cash and cash equivalents">36,865</span> will not provide enough working capital to meet our current operating expenses through the first quarter of fiscal 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The operating deficit and cash balance at July 31, 2023 indicate substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to scale down or perhaps even cease operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are continually adjusting our business plan to reflect our current liquidity expectations. Due to the unknown and volatile nature of the stock price and trading volume of our common stock, it is difficult to predict the timing and amount of availability pursuant to our equity line of credit with Lincoln Park Capital Fund, LLC (“LPC”). Due to the limitations in the equity line of credit, we will need to do one or more of the following during fiscal 2024; secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60097375	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36865	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zFheMyAukgXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zxQmaJbtFPcg">Use of estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Depreciation Depreciation	0	usd
CY2022	us-gaap	Depreciation Depreciation	414	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	3416	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2374	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	3708	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	3685	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	3685	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	3685	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	3685	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	31457	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49905	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54956983	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23696635	shares
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1116020	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2425000	usd
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1580000	usd
CY2023Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	2425000	usd
CY2022Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	1580000	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	2425000	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	1580000	usd
CY2023Q3	ODYY	Unamortized Debt Discount And Closing Costs UnamortizedDebtDiscountAndClosingCosts	280340	usd
CY2022Q3	ODYY	Unamortized Debt Discount And Closing Costs UnamortizedDebtDiscountAndClosingCosts	48063	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2144660	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1531937	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6645000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	6500000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.22
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1350000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.38
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11795000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.34
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y8M26D
CY2022Q3	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	8800000	shares
CY2022Q4	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	8800000	shares
CY2022Q3	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	8800	usd
CY2022Q4	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	8800	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13750	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	14285714	shares
CY2022Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.35
CY2022Q2	ODYY	Minimum Amount MinimumAmount	1000000	usd
CY2023Q3	us-gaap	Common Unit Issued CommonUnitIssued	2870800	shares
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	849302	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1187572	shares
CY2022Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	415650	usd
CY2022Q2	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	374085	usd
CY2022Q2	ODYY	Warrant Issued WarrantIssued	608755	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.35
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	485300	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	885400	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-485300	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-885400	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2960400	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2475100	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2960400	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2475100	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	13745873	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1193602	usd
CY2022Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	820771	usd
CY2023	us-gaap	Other Expenses OtherExpenses	11138	usd
CY2022Q1	us-gaap	Other Income OtherIncome	500000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	261738	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	538135	usd

Files In Submission

Name	View Source	Status
odyy-20230731_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001683168-23-007508-index-headers.html	Edgar Link	pending
0001683168-23-007508-index.html	Edgar Link	pending
0001683168-23-007508.txt	Edgar Link	pending
0001683168-23-007508-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
odyssey_ex1038.htm	Edgar Link	pending
odyssey_ex1049.htm	Edgar Link	pending
odyssey_ex2301.htm	Edgar Link	pending
odyssey_ex3101.htm	Edgar Link	pending
odyssey_ex3102.htm	Edgar Link	pending
odyssey_ex3201.htm	Edgar Link	pending
odyssey_ex3202.htm	Edgar Link	pending
odyssey_i10k-073123.htm	Edgar Link	pending
odyy-20230731.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
odyy-20230731_cal.xml	Edgar Link	unprocessable
odyy-20230731_def.xml	Edgar Link	unprocessable
odyy-20230731_lab.xml	Edgar Link	unprocessable
odyssey_i10k-073123_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ODYY
Odyssey Group of Companies Stock $odyy

2023 Q4 Form 10-K Financial Statement

#000168316823007508 Filed on October 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ODYY Odyssey Group of Companies Stock $odyy

2023 Q4 Form 10-K Financial Statement

#000168316823007508 Filed on October 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ODYY
Odyssey Group of Companies Stock $odyy